Načítá se...
Immunotherapy for Type 1 Diabetes – targeting the innate immune system
Moran et al report two trials of antagonism of the pro-inflammatory cytokine, IL-1, assessing the monoclonal antibody canakinumab and the IL-1 antagonist, anakinra in new-onset Type 1 Diabetes (T1D). The studies both showed that, although relatively safe, there was no efficacy in terms of halting de...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4048745/ https://ncbi.nlm.nih.gov/pubmed/23732280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2013.103 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|